Avid Bioservices Inc (CDMO)

[JamesGMS]

md - re your brief post below:

I agree James and that partnership is made prior the look ins imo too risky for one big pharma to let another out bid them.

Of course no BP in their right mind would want to get into a real bidding war for PPHM. But also keep in mind that PPHM does not want just any partner. So a price to get into the game NOW - AS A PARTNER - and share whatever minimal risk that still remains - will most certainly require a very substantial {Pharmasett Level} premium, although not an enormous premium as CP has occasionally suggested - but then again not from just any BP out there. This partnership must be much more than just a good fit - it has to be a GREAT FIT if both partners want to truly maximize value in the short and very long term.

So which company out there has developed the reputation of doing great DD - and then moving aggressively and quickly once they complete same ?? And what company has no competing products but has announced that they would like to move aggressively into the I/O space ?? And which company would be ideally situated and highly motivated to work with PPHM to quickly and forcefully develop and then sell Bavi - as well as its progeny - to absolutely everyone ?? Which company has over 24 billion in cash and has "advertised" for some time now that they are looking for their next "Cornerstone Molecule" ?? Which company just added over 1000 new employees and is now in the process of greatly expanding its campus footprint in Foster City, California ??

How much more information AND TIME will they need to complete their DD - seeing as there are COPIOUS amounts of positive data NOW available ?? {see Stephen Worsley's statement from the last CC below}

STEPHEN WORSLEY (VP/Business Dev.):

We were very pleased to announce our collaboration with AstraZeneca in August [8-24-15: tinyurl.com/owlxpsf ] and were even more delighted to announce the expansion of that agreement in October [10-15-15: http://tinyurl.com/q79bkam ].

We believe that AstraZeneca’s enthusiasm for this program is based on the promise & potential of bavituximab. Copious amounts of positive data have consistently demonstrated bavituximab’s therapeutic value & ability to provide solutions to the limitations of currently available treatments.

A deal BEFORE first look-in ?? I wouldn't bet against it. And it will be GILD.

Have a nice evening.

James